Specialty Delivers, but a 16.5% Rally Prices Away the Progress

Results vs. Consensus

Q3 FY2026 scorecard: quarter ended December 31, 2025

Year-over-year financial comparison

Sequential comparison

Adjusted EPS bridge from Q3 FY2025

Revenue assessment: The $298M–$498M beat is small for a distributor moving more than $106B of product. Higher retail prescription volumes and oncology distribution explain the growth, but product prices and route-to-market mix influence revenue without producing equivalent profit. The stronger evidence is the profit guidance raise with North American revenue guidance unchanged.

Margin assessment: Adjusted operating profit includes $74M of other income, whereas GAAP operating income is measured before that line. The adjusted margin improves only 2 basis points even as the expense-to-gross-profit ratio falls to 56.9% from 58.3%. Scale still works, but its visible benefit is much smaller than Q2’s 570-basis-point ratio improvement, which also benefited from divestiture comparability.

EPS assessment: The expected tax reversal arrived at the low end of the 23%–25% Q3 range. That explains much of the sequential EPS decline, while the year-over-year tax comparison still helps. GAAP EPS exceeds adjusted EPS because a $160M pretax Rite Aid credit contributes $0.95 per share and is removed from the adjusted series. Positive amortization, transaction and restructuring exclusions total $0.85 per share before offsets from LIFO and legal gains. A net negative adjustment is therefore not evidence that recurring acquisition costs have disappeared.

Segment Performance

North American Pharmaceutical: the earlier margin trigger needs qualification

At $872M, profit grows less quickly than the 9% increase in revenue. That fails our Q2 expectation for a second consecutive quarter of margin expansion. The important counterweight is the $19M held-for-sale benefit in the prior-year Canadian business: removing it from the comparison produces roughly 8.6% profit growth and a prior margin of 0.99%, essentially equal to this quarter. The headline contraction is real; it is weak evidence of a new collapse in distribution economics.

“As a reminder, prior-year results included a $19 million benefit from held- for-sale accounting related to the sale of our Canada-based Rexall and Well.ca businesses. The prior-year held- for-sale accounting benefit had an approximate 3% impact on year-over-year segment growth.”
— Britt Vitalone, CFO

Assessment: The oligopoly operating-leverage pillar remains on track, but the smooth margin-expansion thesis is not confirmed. We give more weight to the 3-point annual profit guidance raise and strength in health-system specialty distribution than to a 2-basis-point reported decline. Neither supports extrapolating a new margin step-up into fiscal 2027.

Oncology & Multispecialty: organic profit clears the prior floor

The $366M profit result combines acquired provider platforms with continued specialty distribution growth. Management reports 15% organic profit growth excluding acquisitions, above Q2’s 13% and within the long-term 13%–16% objective. Organic revenue rises 24%. Provider additions and treatment volumes support a recurring growth case even after the large acquired contribution leaves the comparison.

Assessment: The standing specialty pillar strengthens on organic delivery. Sequential profit falls from $397M, but Q2 included $51M of nonrecurring gains: against the $346M gain-adjusted comparison, profit grows 5.8%. Revenue grows 8.0%, so the gain-adjusted margin still slips about 6 basis points. The business grows, but this is not sequential margin acceleration.

Prescription Technology Solutions: the network earns through investment

Profit rises 18% to $277M on revenue growth of 9%, extending the strongest margin economics in the portfolio. Access services, including prior authorizations, drive the profit improvement. The annual-verification season begins in January, after the reported quarter, and its early volume evidence supports the new annual outlook rather than explaining December-quarter actuals.

Assessment: The prior commitment to sustain growth through higher investment is tracking. We lift our FY26 profit forecast to 16% growth, the new midpoint, while allowing for the explicit $0.05 fourth-quarter technology cost. Half of segment revenue comes from third-party logistics, so changes in the mix of services matter more than the top-line growth rate alone.

Medical-Surgical: a weak illness season persists into separation planning

Revenue edges up 1%, helped by specialty pharmaceutical volumes, but lower physician-office volumes and seasonal illness reduce profit 10%. The 111-basis-point margin contraction matters more than the revenue result. After the already cautious Q2 outlook, the business is now relying on Q4 to limit full-year weakness.

“Moving now to the Medical-Surgical Solutions segment, we anticipate revenue and operating profit at the lower end of 2% to 6% growth. We're closely tracking the development of the current illness season. We've observed a soft illness season demand in our fiscal third quarter. In the second half of December, illness severity levels peaked based on CDC data. Variability remains a key factor. Timing, severity and the duration of each illness season can drive variation and meaningfully affect results on both a quarterly and annual basis.”
— Britt Vitalone, CFO

Assessment: The recovery watch item remains unmet. Our 2% annual profit-growth assumption requires roughly $284M of Q4 profit, broadly flat with last year’s $285M. That is achievable after the Q3 decline, but it leaves little cushion for a shorter illness season and weakens the earnings story being prepared for public-market investors.

Corporate and Other: costs become more visible

Corporate expense increases to $156M from $132M, including technology infrastructure spending, despite Ventures gains rising to $11M from $6M. Removing those gains gives $167M of cost versus $138M, a 21% increase. Norway contributes $28M of adjusted profit in the quarter before its January disposal.

Assessment: The specialty improvement must fund a real central-cost burden. Raising the corporate expense floor and minority-interest range partly absorbs operating gains, while Norway’s sale removes a profitable contribution from the next fiscal year. We retain both offsets in the earnings bridge.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management remains confident, as in Q2, and is more specific about the operating examples behind its technology investments. The responses are least conclusive where investors need a quantified margin runway, post-acquisition growth cadence or net separation value.

1. Automation supports the profit bridge as expense leverage moderates

The enterprise still spends a smaller share of gross profit on operating expenses than a year ago. Unlike Q2, however, absolute adjusted expenses rise 7%; acquired businesses and technology spending consume part of the efficiency benefit. Expense leverage is moderating as efficiency gains coexist with reinvestment; the ratio does not isolate an enterprise savings rate.

“In the US, we launched an AI chat tool in November to specifically handle customer inquiries related to the Drug Supply Chain Security Act. By enabling natural language answers to complex DSCSA data questions, we prevented 75% of inquiries from being escalated and materially improved from first contact resolution. These are strong examples of how we're using technology to simplify the supply chain at scale, while improving customer experience.”
— Brian Tyler, CEO

Assessment: Avoiding escalation of routine compliance inquiries provides a credible route to lower support costs. It does not establish an enterprise-wide savings percentage. Our forecast relies on operating-profit growth within the published ranges and assigns no separate AI valuation premium.

2. Provider scale must survive the acquisition anniversary

The 15% organic oncology profit result is the clearest answer to the Q2 concern that the segment’s growth was mainly purchased. But the full-year reported profit outlook of 51%–55% still includes an acquisition contribution of approximately 30–34 percentage points. The transition to organic growth becomes more visible as PRISM laps its April 2025 closing and Core Ventures its June closing.

“Today, the US Oncology Network has approximately 3,400 providers and PRISM Vision brings together over 200 providers in retina and ophthalmology. During the quarter, we continued to make progress in the integration of Florida Cancer Specialists and PRISM Vision, contributing meaningfully to the strong performance of the segment.”
— Brian Tyler, CEO

Assessment: Practice density can increase distribution throughput and spread administrative infrastructure across more providers. We use 14.5% oncology profit growth in FY27, within the organic target, rather than extending the acquisition-assisted FY26 rate. That makes recruitment, retention and same-practice activity the relevant next tests.

3. Access investment has a near-term cost and a wider addressable workflow

Digitizing enrollment for more than 1,600 specialty medications extends McKesson’s technology services further into specialty care. Faster processing can make programs more useful to manufacturers and providers; it does not by itself measure additional prescriptions or incremental profit. The January verification program has better volumes, while the expense commitment remains.

“Our improved full year outlook reflects the strength of our annual verification program and we've observed meaningful year-over-year volume increases through the end of January. Our full year outlook also anticipates technology infrastructure and capability investment. We anticipate fiscal fourth quarter technology investments to be an approximate $0.05 incremental cost as compared to the prior year.”
— Britt Vitalone, CFO

Assessment: Raising the profit range despite the spending is a pass on the previous investment test. The forecast benefit comes from higher access volumes and operating efficiency; we do not assume every newly digitized medication becomes incremental program revenue.

4. Pricing resilience enters the outlook before it enters reported results

January’s Medicare Part D price changes fall outside the December quarter. They are included in the raised annual guidance, and management says manufacturer negotiations have retained service economics. This is better evidence than the wholly qualitative reassurance available at Q2, but it remains an outlook statement for the new policy regime.

“As it relates to IRA Part D, the first 10 drugs that went live just went live in January. So, that's obviously not in our Q3 numbers, but it is in the increased guidance range that we have provided to you. And as you know, these kinds of things are – they happen routinely. And so, we sit down with our manufacturing partners continuously and talk about the evolution in their portfolios and their pricing strategies and the value that McKesson brings, and speak in a very constructive way, we feel good about how those conversations have progressed.”
— Brian Tyler, CEO

Assessment: We reduce the policy risk tag from MATERIALIZING to EMERGING. The old tag had escalated because disclosure narrowed, without a measured earnings impact; the explicit incorporation of January pricing into a higher guide warrants that recalibration. Future fee renegotiations and community-provider reimbursement still justify a discount to a frictionless growth case.

5. Separation progress comes with a less precise endpoint

Transition service agreements took effect January 1, a concrete step toward an independent Medical-Surgical organization. Yet the milestone described this quarter is an IPO by the second half of calendar 2027, whereas Q2 described completing the separation by that period following an IPO and lockup. Those are different endpoints.

“We continue to focus on the next steps which include establishing an independent organization and capital structure. We continue to track towards the timeline of an IPO by the second half of calendar 2027, subject of course to market conditions and customary regulatory approvals.”
— Brian Tyler, CEO

Assessment: We do not infer a formally announced delay, but the prior full-exit commitment is no longer clearly reaffirmed. Combined with the absence of recurring stranded-cost estimates, that moves the portfolio pillar from ON TRACK to AT RISK despite procedural progress. Our valuation includes consolidated medical earnings and no incremental separation premium.

6. Norway closes earlier than the prior outline, removing future contribution

The January 30 disposal finishes the European exit. Q2 had anticipated closing after fiscal 2026; the business now contributes approximately $1B of revenue and $70M of adjusted operating profit to this fiscal year. Held-for-sale EPS accretion falls to approximately $0.10 from $0.13, including $0.05 in Q3.

“In the third quarter, held-for-sale accounting for Norway contributed $0.05 to adjusted earnings per diluted share. For fiscal 2026, we now anticipate the Norwegian businesses to contribute approximately $1 billion of revenue and approximately $70 million of adjusted operating profit, which is inclusive of approximately $0.10 of adjusted earnings per share accretion due to held-for-sale accounting.”
— Britt Vitalone, CFO

Assessment: The $0.40 guidance midpoint raise absorbs a further $0.03 reduction in the accounting benefit. The revision therefore contains more improvement elsewhere than its headline suggests, although tax, minorities and corporate cost prevent calling the entire difference operating profit. The European exit simplifies the business while creating a roughly $70M operating-profit headwind in our FY27 bridge.

7. Cash conversion improves, without raising the annual cash promise

Nine-month free cash flow is $2,174M versus negative $2,244M a year earlier. The receivables, inventory and payable movements together consume $1,337M of cash versus $4,521M, an improvement of $3,184M. That explains much of the cash recovery and also shows why the $9.6B trailing-twelve-month figure is not a recurring annual run rate.

“Wrapping up our outlook with cash flow and capital deployment. For fiscal 2026, we anticipate free cash flow of approximately $4.4 billion to $4.8 billion. Our outlook includes plans to repurchase approximately $2.5 billion of shares, with weighted average diluted shares outstanding of approximately 124 million.”
— Britt Vitalone, CFO

Assessment: The unchanged $4.4B–$4.8B forecast requires $2.226B–$2.626B in Q4. The earlier second-half cash watch item is progressing, with $1.057B delivered in Q3, but the stronger trailing result does not warrant a cash-flow multiple expansion. Supplier-payment and inventory timing remain large enough to overwhelm a single quarter of operating improvement.

8. Minority ownership is a continuing economic claim

Debt falls to $6.557B and cash to $2.959B following $1.199B of year-to-date debt repayments. Net debt of $3.598B is manageable against annual cash generation. Alongside it, redeemable minority interests rise to $802M from $777M at September 30, with a $25M Core Ventures redemption-value adjustment in Q3 and $72M across the acquired platforms year to date.

These are existing ownership claims, not a new $25M cash payment or an operating expense. The Core minority put is exercisable every five years, subject to a floor of 75% of its initial fair value. The quarter’s remeasurement reinforces a concern already raised in Q2: the minority owners participate in the platforms’ appreciation as well as their earnings.

Assessment: We move the adjusted-economics risk from CONTAINED to EMERGING because recurring valuation changes expose a cost of ownership that the adjusted EPS headline does not describe. The exclusion of the Rite Aid credit remains appropriate. Our bridge deducts ordinary adjusted minority expense, while the redemption exposure limits the multiple we are willing to assign rather than being charged again as current operating cost.

Guidance & Outlook

FY2026 consolidated outlook

FY2026 segment outlook

Remaining-quarter hurdle: Nine-month adjusted EPS of $27.46 leaves approximately $11.34–$11.74 in Q4, versus $10.12 a year earlier: 12.1%–16.0% growth and a 21.4%–25.7% sequential increase. Quarterly share weighting creates small differences between summed EPS and the annual measure. Our full-year bridge implies about a 14.8% Q4 tax rate to reach 19% for FY26, after 20.6% through nine months. A large sequential tax benefit remains part of the fourth-quarter shape.

North American profit guidance requires roughly $925M–$1,050M in Q4, or 4.5%–18.7% year-over-year growth after 6.1% in Q3. The annual range is still four percentage points wide; translating that range into a single remaining quarter creates the wide quarterly interval. The raised midpoint is credible given the Canadian comparison and specialty volumes, but it is not a narrow promise of double-digit quarterly growth.

Street and guidance style: The $39.00 new EPS midpoint is $0.30 above the contemporaneous $38.70 full-year estimate. This is another upward revision, with a narrower EPS range and broad operating support. Higher tax and minority allocations consume some of that support, so the guide’s quality is stronger than a simple beat-and-raise label but its remaining-quarter execution burden is still meaningful.

Analyst Q&A Highlights

Can manufacturer price cuts leave service earnings intact?

The last exchange separates drug-price revenue effects from the compensation earned for distribution services. It directly tests the policy discount embedded in our earlier Hold case.

Q: “But we know that going into your fiscal fourth quarter, we're going to see a significant number of brand drug manufacturers take price decreases. It doesn't look like it's going to hit your income statement at all, either at the revenue line or at the operating earnings line. But Britt, I would just love if you could opine what you've seen from pricing actions from branded drug manufacturers, whether we should expect to see any impact. I know that you don't want to speak to fiscal 2027. And I'd love to hear you talk about how McKesson's negotiated around its value proposition and maintain its economics.”
— George Hill, Deutsche Bank

A: “We've maintained very strong relationships with our manufacturing partners, and we have continual conversations with them about the products that they need us to support and about the fair value for the services that we provide. So, we've continued to have very constructive conversations. We've continued to maintain the value that we're providing in our pricing and our agreements with the manufacturers. And what we've seen thus far in terms of pricing activity and changes in prices has been right in line with our expectations. There's really nothing out of line and really consistent with what we've seen over the past few years. So, there's been a lot of changes over the last several months, but nothing that has impacted our economics, at least from a bottom line perspective. Pricing declines will have an impact on revenue, but it's not really material to our results. And I think we're really pleased with the strength of the relationships that we have with our manufacturing partners and the ability to retain the value.”
— Britt Vitalone, CFO

Assessment: Manufacturer negotiations have preserved service economics despite pressure on drug-price revenue. It supports a resilient near-term profit forecast, not immunity to every future pricing arrangement. We require the first quarter of reported January-policy economics before treating the risk as contained.

The oncology margin premise does not survive the comparison

The exchange identifies provider mix, specialty products and early automation benefits. Its numerical premise needs a different conclusion from the qualitative answer.

Q: “So if I go back to last quarter, you talked about $51 million of a nonrecurring gain in oncology and multispecialty. So, actually, if I back that out, it looks like the margin improved in that division by nearly 100 basis points. So, you also made the comment today that between PRISM and Core Ventures that the contribution is still roughly the same as what you said last quarter, 30% to 34%. So, I want to ask the question in a different way. It appears to me that the margins are improving quarter-over- quarter. And I'm just curious what's driving that? I know at our conference, you, Brian, and I talked about, for example, ambient scribing, making the physician more effective. We talked about biosimilars. Is there anything you would call out specifically as to what's driving that margin improvement and how we think about that going forward?”
— Lisa Gill, JPMorgan

A: “Yeah, it's a good point, Lisa. And again, that gain that you mentioned that was in the second quarter. As we added the providers to the platform for Florida Cancer, as we've continued to build out our Vision platform, those are positive mix attributes to the segment. We're also seeing continued growth in specialty, and specifically in oncology products. So, those are favorably impacting the overall operating margins of the segment. And to the point that Brian made, we are early in our journey of automating and building AI capabilities for our customers, but we are seeing that have an impact. And we would expect that impact will continue to build over time. Quarter-to-quarter, you'll have some variability. You'll have some mix variability. But overall, as I mentioned in my comments to Brian, we believe that the additions of both PRISM and Florida Cancer are accretive, not only to revenue and operating profit dollars, but also to the margins over time.”
— Britt Vitalone, CFO

Assessment: Removing Q2’s $51M gain gives a 2.87% prior margin, versus 2.81% now, a decline of about 6 basis points. Management did not establish the question’s claimed sequential improvement. Its explanation supports long-term mix accretion, while the actual quarterly data favor steady growth over a margin breakout.

Acquisition integration is on plan; the standalone service growth rate is still missing

The question seeks both acquisition delivery and a view of the management-services business excluding distribution.

Q: “So as it relates to PRISM and FCS, I guess, can you speak a little bit more about how the transactions are progressing? You maintain the guidance expectation in terms of the contribution for those deals. Is that true for both assets? And anything you can break down in terms of underlying MSO business growth and how we should think about that longer term? Anything to call out that you're seeing now on the MSO side, excluding or stripping out that distribution component of that segment?”
— Erin Wright, Morgan Stanley

A: “Yeah. Well, I would say that we maintained the full year – the year-one accretion guide that we provided. But as I've mentioned before, not only are we pleased with the business, we're pleased with the integration, we're pleased with the volumes that we're seeing thus far. We did make a small acquisition to add to the PRISM platform earlier in the fiscal year. And I think, generally speaking, both businesses are performing on their acquisition case, in the case of PRISM, maybe slightly ahead.”
— Britt Vitalone, CFO

Assessment: Maintaining the original accretion commitments is a pass, and PRISM may be ahead. Stable and growing volumes strengthen the organic case, but the response supplies no standalone MSO growth rate. Our forecast uses the disclosed segment organic range rather than assigning the entire reported mix a service-business multiple.

Oral GLP-1 demand may expand the network, but substitution is unresolved

The question tests whether new oral users can sustain prior-authorization growth beyond the current verification season. Management acknowledges early activity without treating it as proof of a larger net patient pool.

Q: “You had called out earlier you've made positive comments about annual verifications. I'd love a little bit more color on that. And also, do you see GLP-1s possibly introducing new utilizers on the prior authorization side? Is that part of the thing that's giving you more confidence in the business? How is that trending? How should we think about it? I think we're all wondering sort of how RxTS is going to continue to grow at the same pace into fiscal 2027 and beyond and what the other drivers are. So if you can expand on those two, that'd be great.”
— Kevin Caliendo, UBS

A: “Yeah. Look, it's very early days for the oral GLP-1 launch, so it's really hard to try to dissect trends from the – given the size of the injectable market versus a few weeks of launch of the oral drug. But we are seeing some prior authorizations come through there. I think we'll have to track this over time. I mean, I don't think anyone could tell you what share of GLP-1 oral growth will come at the expense of the injectable or what share of it will be net new customers. So, that's something that we'll watch. But we're very confident the category will continue to grow.”
— Brian Tyler, CEO

Assessment: Oral growth may replace injectables or add patients; the net demand benefit remains unknown. This leaves the Q2 cash-pay question open and prevents us from building a second demand boost on top of the existing access forecast. Broader program additions provide stronger current evidence than a few weeks of oral-product experience.

Does internal technology spending displace acquisitions?

The capital-allocation question asks whether the next growth phase changes the balance between building capabilities and buying them. The response keeps both routes available.

Q: “Given the IT investments you talked about in response to Allen's questions, and certainly make sense in the long-term vision of the company, if we think about your cap deployment priorities, and you've always talked about this portfolio management, should we expect sort of a shift more towards those internal growth investments versus what we've seen recently in terms of being more acquisitive? Or would we expect a sort of continuation of what we've seen in the historical pattern?”
— Elizabeth Anderson, Evercore ISI

A: “Yeah, I don't think we've changed our philosophy at all. And we have continuously, for the last many years, been investing back into our businesses to innovate new products, add new features, extend our differentiation. And we've similarly deployed capital sometimes to acquire capability that we think is better to acquire than take the time to build internally. But our capital allocation framework is still the same. We still are excited about the opportunities we have to continue to scale through inorganic acquisitions that are aligned to our strategy, that fit our business model, and that meet our financial returns. But our first priority is always to invest back in the growth of the business. And that can take two forms. That could be internally, we can invest in people, technologies, other resources to help expand the differentiation and expand maybe our market opportunities; or we can do it through – inorganically. And I think we've got a successful track record of doing both, and we would look to continue that.”
— Brian Tyler, CEO

Assessment: Management answers the strategic question clearly. Acquisition discipline still matters because the platforms carry minority claims and integration costs as well as operating profit. We forecast organic growth and continuing buybacks, with no undisclosed acquisition accretion or disposal windfall.

What They're NOT Saying

1. Net recurring separation cost and a reconciled endpoint. Transition agreements establish operating arrangements, but neither their recurring economics nor the relationship between an IPO by 2H 2027 and the earlier full-exit objective is clear. This prevents a reliable incremental separation valuation.
2. A standalone MSO growth and margin series. Organic segment profit clears 13%, but distribution, existing practices and new providers remain blended. The unanswered split determines how much growth deserves a service-business valuation after acquisitions lap.
3. GLP-1 channel profit and cash-pay substitution. The $14B sales figure is still a call disclosure, with no corresponding GLP-1 series in the 10-Q. Early oral authorizations do not resolve net new patients versus switching or identify the earnings split between distribution and access services.
4. The durability of the cash improvement. Working-capital movements explain much of the year-to-date recovery, while the annual cash outlook is unchanged. Supplier-payment and inventory timing need to normalize before the trailing $9.6B can support a higher recurring cash estimate.
5. A quantified FY27 bridge. Formal guidance is deferred to May. Acquisition anniversaries, Norway’s exit, taxes, minority earnings and reinvestment make the long-term EPS algorithm an aspiration rather than a one-year guarantee.

Market Reaction

• Pre-print setup: MCK entered the release at $822.00, up 0.2% year to date, up 36.2% over twelve months and down 0.4% over thirty days. The prior 52-week closing range was $593.69–$889.28.
• February 5 reaction session: The stock opened at $862.00, a 4.9% gap, traded between $862.00 and $971.93, and closed at $957.80, up 16.5% or $135.80. Volume was 2.2M shares, 4.0 times its trailing 30-session average.
• Relative performance: The S&P 500 fell 1.2%. Cencora gained 6.7% and Cardinal Health gained 9.8% over the same session, indicating a broader distributor bid as well as MCK-specific outperformance.

Our interpretation is that investors paid for confidence in durable specialty growth and pricing resilience, not just the small December-quarter beat. The large moves in peers support a sector component; the daily data cannot isolate how much of McKesson’s rally came from its own call, positioning or broader defensive demand.

The valuation consequence is less ambiguous. Before the print, $822.00 was 21.3 times the prior $38.60 annual midpoint. At $957.80 against the new $39.00 midpoint, it is 24.6 times. The roughly 1% increase in annual EPS guidance cannot account for a 16.5% share-price gain. This is a substantial increase in what investors will pay for each dollar of earnings, exactly the risk that kept the prior rating at Hold.

Street Perspective

Debate: does specialty strength outweigh the core margin reversal?

Bull view: The larger growth platforms deliver double-digit profit expansion and the core annual profit guide rises despite January drug-price changes. That is a stronger signal than a small quarterly margin movement.

Bear view: Core profit grows slower than revenue and expense leverage moderates. Acquisition contributions and provider additions complicate the case for a sustained step-up in underlying margins.

Our take: The bulls have the stronger operating argument because the Canadian accounting lap largely explains the core margin decline and oncology organic profit clears the prior floor. We preserve the operating pillars, but the quarter does not demonstrate the acceleration implied by the stock’s re-rating.

Debate: can the service platforms sustain the new growth identity?

Bull view: Community practice support and biopharma access embed McKesson in customer workflows beyond physical distribution. Organic oncology growth and new access programs show demand for that broader offering.

Bear view: Reported oncology profit growth remains heavily acquisition-assisted, half of RxTS revenue is logistics, and Medical-Surgical has not yet left the portfolio. A blanket service-platform multiple would overvalue the lower-margin pieces.

Our take: The service case is credible enough to forecast another year of growth, with 14.5% oncology and 11.5% RxTS profit increases. It is not grounds to erase the lower-growth distribution base, minority participation or separation costs from valuation.

Debate: how much protection does defensive demand offer at this price?

Bull view: Stable utilization, high cash generation and a rising outlook deserve a premium when market leadership is under pressure. The industry’s shared rally is consistent with that positioning.

Bear view: Defensive earnings do not guarantee defensive share prices once the multiple reaches 24.6 times the current-year guide. The separation milestone remains distant and the earnings revision is small.

Our take: Price now outweighs operating progress. Our base case retains a premium to the 19-times entry multiple preferred in Q2 but still produces a modest negative total return. Underperform reflects that prospective return gap, not an expectation that prescription demand contracts.

Our Estimates & Valuation

Earnings bridge: current year to fiscal 2027

FY26 segment estimates apply the growth assumptions to recast FY25 profits of $3,145M, $936M, $961M and $1,022M. The resulting $6,483.8M consolidated adjusted profit grows 15.4% and yields $38.95 EPS, inside the new $38.80–$39.20 guide. Q4 pretax profit of approximately $1,721.8M and tax of $255.2M reconcile the annual bridge to the nine-month actuals.

FY27 is our forecast, not company guidance. It produces approximately 12.5% EPS growth, slightly below the 13%–16% long-term algorithm as Norway disappears and minority earnings rise. The share assumption depends on continued capital returns; it is not a newly announced buyback commitment. Medical-Surgical remains consolidated for the full fiscal year. No new acquisition, transaction proceeds or separation premium is included.

A one-point lower core profit-growth assumption changes FY27 EPS by about $0.23; a one-point higher tax rate reduces it by about $0.57; one million additional diluted shares reduces it by about $0.36. These sensitivities show why another strong segment quarter alone cannot settle the shareholder earnings outlook.

12-month return framework from the $957.80 reaction close

Returns include $3.28 of assumed dividends over the next twelve months, holding the $0.82 quarterly rate constant, and use the same February 2027 horizon in every case. We compare them with an 8% assumed S&P 500 total return. Our base return trails that benchmark by roughly 12 percentage points.

We introduce a 12-month scenario valuation, extending Q2’s preferred entry near 19 times FY26 earnings and its indicative FY27 EPS range of $43.60–$44.80. The new $43.80 estimate sits within that range. Our 21-times FY27 base multiple credits the stronger service mix and steady utilization while allowing for slower reported growth after acquisition anniversaries, minority claims and an unresolved separation. It sits below the current 21.9-times price-to-FY27 estimate and above Q2’s preferred entry multiple on FY26 earnings.

The bear case combines weaker core growth, oncology below its organic target or higher tax and separation costs with a return to a 19-times valuation. The bull case requires earnings above our operating bridge and sustained investor willingness to pay 24 times those earnings, supported by stronger platform growth and pricing resilience. The favorable business trajectory makes that outcome possible; it does not make the current price attractive on our central assumptions.

Thesis Scorecard Post-Earnings

Prior commitments: Q3 tax lands inside 23%–25%; the second core-margin expansion does not arrive; RxTS handles the investment step-up; oncology organic growth improves before the acquisition anniversaries. The second-half cash target remains achievable. Medical-Surgical recovery, recurring stranded costs, a filed GLP-1 earnings series and FY27 acquisition-anniversary guidance remain outstanding. Q3 EPS growth still benefits from tax and share count, so the earlier test of assistance-free second-half growth is not fully satisfied.

What changes the view: A price nearer the 19-times entry framework with operating estimates intact, reported preservation of fees through January pricing changes, or quantified net separation value would improve prospective returns. Organic oncology below its 13% floor, core profitability weakening beyond the Canadian comparison, or a FY27 outlook below the earlier $43.60–$44.80 range would move the case toward our downside. The prior 2H calendar 2027 full-exit objective remains a commitment to clarify, not one we declare completed.

Overall: The specialty and access businesses strengthen the operating thesis, while the core margin test and separation endpoint are less reassuring than the headline rally suggests. Conviction remains 6 out of 10. The principal change is the price investors now pay for a still-attractive business.

Action: Downgrade to Underperform from Hold. At $957.80, the forecast offers insufficient return against the S&P 500 and meaningful downside if the premium moderates. A higher earnings estimate and a lower rating are consistent: the stock has risen far more than the earnings we can presently underwrite.